Watch an interview with the Director of UPMC Clinical Test Development Laboratory, Dr. Aatur Singhi, on Pittsburgh Today Live, as they discuss the importance of early testing and detection when fighting Pancreatic Cancer.
Watch an interview with the Director of UPMC Clinical Test Development Laboratory, Dr. Aatur Singhi, on Pittsburgh Today Live, as they discuss the importance of early testing and detection when fighting Pancreatic Cancer.
NEW YORK – In a prospective study of more than 1,800 patients at 31 clinical centers in the US, the PancreaSeq test developed at the University of Pittsburgh surpassed currently used guidelines for correctly classifying potentially cancerous pancreatic cysts.
Singhi AD, McGrath K, Brand RE, Khalid A, Zeh HJ, et al. Gut. 2018 Dec;67(12):2131-2141.
Bell PD, Singhi AD. Surg Pathol Clin. 2022 Sep;15(3):455-468.
Singhi AD, Wood LD. Nat Rev Gastroenterol Hepatol. 2021 Jul;18(7):457-468.
Singhi AD, Wood LD, Parks E, Torbenson MS, Felsenstein, et al. Gastroenterology. 2020 Feb;158(3):573-582.e2.
Singhi AD, Zeh HJ, Brand RE, Nikiforova MN, Chennat JS, et al. Gastrointest Endosc. 2016 Jun;83(6):1107-1117.e2.
Singhi AD, Nikiforova MN, Fasanella KE, McGrath KM, Pai RK, et al Clin Cancer Res. 2014 Aug 15;20(16):4381-9.
Nikiforova MN, Khalid A, Fasanella KE, McGrath KM, Brand RE, et al. Mod Pathol. 2013 Nov;26(11):1478-87.
PancreaSeq is a product of the Molecular & Genomic Pathology Laboratory at the University of Pittsburgh Medical Center.